Activins are members of the transforming growth factor β (TGFβ) superfamily of growth and differentiation factors. Homoor heterodimeric activin proteins are formed by linking βA-or βB-subunits through disulphide bonds, and at least three forms of activins with biological activity have been described: activin A (βAβA), activin B (βBβB) and activin AB (βAβB) (de Kretser et al., 1999) . The isolation of activins followed that of inhibins, which are dimeric proteins composed of an α-and a β-subunit (de Kretser, 1990) . In both cases, the purification of these proteins was led by the search for gonadal proteins that could regulate pituitary FSH secretion; whereas activin stimulated pituitary FSH release, inhibin was inhibitory (McLachlan et al., 1987) . As well as the regulation of FSH, dual opposing roles for activin and inhibin were described in the regulation of testicular steroidogenesis (Hsueh et al., 1987) , and it was viewed that these proteins balanced one another in their specific actions on target tissues.
The main source of inhibin in the circulation is the gonads, in which there is an inverse correlation between serum inhibin A or inhibin B and FSH concentrations, confirming the endocrine action of inhibin. In contrast, gonadal activin is not the major source of circulating concentrations of activin, as activin is synthesized in a broad range of tissues (Roberts and Barth, 1994; Ying et al., 1997a) . With increasing age, the changes in activin concentrations in men and women (reported by Loria et al., 1998) did not correlate with those of FSH, and were not related to gonadal changes. Thus, circulating activin is not a major regulator of FSH and activins are viewed as paracrine, rather than endocrine, agents (Welt and Crowley, 1998) .
The diverse tissue distribution of activins is matched, in many instances, with the co-expression of follistatins. Follistatins are unrelated glycoproteins that inhibit FSH secretion and act as activin-binding proteins (Sugino et al., 1997) . There are many examples of the cell-and tissue-specific manner in which follistatins modulate activin activity (Sugino et al., 1997) . In general, follistatin concentrations exceed those of activin, and it appears that most of the circulating pool of activin is bound to follistatins and, therefore, is not biologically active.
The testis is not the only source of activin in the male reproductive tract, and there are several reports of activin subunit mRNA and protein expression in the prostate, seminal vesicles, and epididymis (Kaipia et al., 1994; Majdic et al., 1997; Roberts, 1997; Thomas et al., 1997 Thomas et al., , 1998 Ying et al., 1997b; Jarred et al., 1999) .
Expression and synthesis of activins in the testis
Numerous studies have examined the expression of activin subunit mRNAs and proteins in the testis, mainly in rodent tissues but also in ovine, bovine and primate tissues. The purpose of this review is not to document every report describing activin subunit expression, bur rather to emphasize the precise cellular localization of subunit expression consistent with the role of activins as paracrine or autocrine agents.
Several studies have used RT-PCR and northern blot analysis to examine testicular expression of activin subunits, while fewer studies have specifically identified cellular activin expression by in situ hybridization ( Kaipia et al., 1992 ( Kaipia et al., , 1994 Yamamoto et al., 1996; Majdic et al., 1997; Roberts, 1997; Davis and Johnson, 1998; Jarred et al., 1999) . In the fetal testis, mRNA encoding activin βA is expressed by Sertoli and Leydig cells,
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The localization of activin proteins in the testis was reported by several groups (Kaipia et al., 1994; Yamamoto et al., 1996; Majdic et al., 1997; Roberts, 1997; Davis and Johnson, 1998; Jarred et al., 1999) . Briefly, in the fetal testis, βB-subunit was localized to Sertoli and Leydig cells, and βA-subunit was localized to Sertoli, Leydig and germ cells (Jarred et al., 1999) . Activin βB-subunit was localized to Sertoli cells throughout development and in the adult testis (Majdic et al., 1997; Andersson et al., 1998) , and βA-subunit was detected in the Leydig and Sertoli cells of the adult testis (Bhasin et al., 1989; Wada et al., 1996; Yamamoto et al., 1996) . However, these studies on protein localization are not always consistent; for example, when two studies used the same antibodies directed against activin βA-subunit, one group localized βA to the fetal testis (Jarred et al., 1999) whereas another did not (Majdic et al., 1997) . There are several reasons why reports of the same protein may differ among groups. If there is a net decrease in protein production at one age relative to another, the sensitivity of the method of protein detection is critical. The ability to detect proteins is dependent on the particular immunohistochemical method used and the sensitivity may differ from one laboratory to another, yielding disparate data. In recent years, antibodies generated by the Groome laboratory have been commonly used to detect activin βA-or βB-subunit proteins. Although the βA-antibody is highly specific, the βB-antibody has a 1% crossreactivity with the activin βA-subunit (Illingworth et al., 1996) . Therefore, it is necessary to block epitopes to the βA-subunit before detection of the βB-subunit. Jarred et al. (1999) reported a differential localization of βA-and βB-subunit in ovine tissues.
It is important to determine the exact cellular localization of the activin subunit proteins because the synthesis of dimeric proteins relies on co-localization of subunits within the same cell; protein dimerization occurs intracellularly before secretion (de Kretser et al., 1999) . Thus, the co-localization of activin subunits indicates the capacity of a cell type to form activin dimers. For example, in the fetal testis, Sertoli and Leydig cells have activin βA-, βB-and inhibin α-subunits and, therefore, can produce all known activins (activin A, AB and B) and inhibins (inhibin A and B). However, activins but not inhibins are products of the fetal germ cell population, because fetal germ cells express activin βA-and βB-subunits but not inhibin α-subunit and, therefore, have the capacity to synthesize only activins. In the adult testis, Sertoli cells have the potential to synthesize all known activins and inhibins, and Leydig cells have the capacity to synthesize activin A and inhibin A (Kaipia et al., 1992; Wada et al., 1996; Yamamoto et al., 1996; Majdic et al., 1997) . The production of specific activins or inhibins by cells is only the first step in the pathway to biological action. After ligand synthesis, a biological action is dependent on the presence of appropriate activin receptors and intracellular signalling molecules such as Smads. Many of the activin receptors are present in testicular cells (Feng et al., 1993; Kaipia et al., 1994; Risbridger et al., 1996; Roberts, 1997; Ying et al., 1997b) , which provides a clue to ligand action. However, ligand access to receptors can be modulated extracellularly by activin-binding proteins such as follistatin, as will be discussed below.
Biological activity of activins in the testis
In the testis, both stimulatory and inhibitory effects of activins have been reported, and these effects are also age-and celldependent. In the early fetal testis, DNA synthesis of gonadal organ cultures was inhibited by activin A (Kaipia et al., 1994) . Cultures of testis tubule fragments from 9 day old rats have been used to identify separate effects of activin. While activin A stimulated Sertoli cell proliferation, simultaneously, it inhibited proliferation of differentiating type A spermatogonia (Boitani et al., 1995) . Similarly, in the immature testis, activin A induced germ cell proliferation in co-culture with Sertoli cells (Mather et al., 1990 (Mather et al., , 1993 , but inhibited immature Sertoli cell function (de Winter et al., 1993) . This inhibition of function, which resulted in testicular degeneration, was also reported in transgenic mice with ectopic expression of the activin βA gene in testes 3 weeks after birth (Tanimoto et al., 1999) . In the adult testicular epithelium, the effects of activin A appear more limited; DNA synthesis was stimulated by activin A in the preleptotene spermatocytes and intermediate spermatogonia of microdissected adult rat tubule segments in culture (Hakovirta et al., 1993) . In the interstitial compartment, activin A inhibited the Leydig cell steroidogenesis of adult and fetal testes (GonzalezManchon and Vale, 1989; Lin et al., 1989; Rombauts et al., 1996) .
Many of the testicular effects of activins are modulated by inhibins. The earliest example of dual opposing actions of activins and inhibins was described in the regulation of testicular steroidogenesis, in which inhibin stimulated and activin inhibited testosterone production (Hsueh et al., 1987) . The dual opposing roles of inhibins and activins in the testis were thought to be the result of the dominant-negative effect of inhibin α-subunit on activin β-subunit receptors (Xu et al., 1995) . However, the cloning and identification of a specific inhibin receptor (Wang et al., 1999a) may provide a new perspective on the roles of activins and inhibins. The localization of inhibin receptors on specific cell types will identify potential sites of action of inhibin proteins, and add further complexity to our understanding of the interactions of activins and inhibins.
As well as inhibins, follistatin can restrict activin ligand access to its receptors, and the localization of follistatin in the testis has been described (Majdic et al., 1997; Meinhardt et al., 1998) . In some, but not all, instances, the effects of activins are blocked or antagonized by follistatin (Mather et al., 1993 (Mather et al., , 1997 . Understanding the interplay between activins and follistatins in the testis will require the use of more specific antibodies and reagents to determine the exact localization of follistatin isoforms in relation to activins.
Expression, synthesis and activity of activins in the prostate
The prostate was considered to be one of the first sites of 'inhibin' production in the male reproductive tract. However, many of the early reports describing prostatic inhibin proteins (PIP) explored the physiology of proteins unrelated to dimeric inhibins. In the 1990s, the present authors and others described the expression and localization of inhibin and activin subunits in the rodent and human prostate gland. mRNAs encoding activin subunit were detected by RT-PCR in human prostate (Ying et al., 1997b; Thomas et al., 1998) , and localized by in situ hybridization. In the non-malignant prostate, mRNA encoding βA-subunit was expressed in basal and secretory epithelial cells, whereas expression of mRNA βB-subunit was predominant in basal epithelial cells (Thomas et al., 1997) . Specific monoclonal antibodies showed the localization of βA-and βB-subunit proteins in the prostate was entirely consistent with cellular expression of mRNAs encoding activin (Thomas et al., 1997 (Thomas et al., , 1998 Ying et al., 1997b) . Activins were also localized to prostatic tumours (Thomas et al., 1997) and prostate tumour cell lines (Zhang et al., 1997) . Thus, the prostatic epithelium has the potential to produce activins A, AB and B. Inhibin α-subunit has been localized to prostatic basal epithelial cells (Mellor et al., 1998) , which shows that the basal cells of the non-malignant human prostate can produce all known activins and inhibins (Fig. 1) .
In the prostate, only inhibitory effects of activins have been reported. Most studies have examined the effects of activin A, but few studies have used activin B (McPherson et al., 1997) . The addition of activin A to the prostate cancer cell line LNCaP inhibited cell proliferation and induced apoptosis (Dalkin et al., 1996; Wang et al., 1999b; McPherson et al., 1997 McPherson et al., , 1999 and upregulated the differentiation markers, prostate-specific antigen (PSA) and prostatic acid phophatase (PAP) (Zhang et al., 1997) . However, the response to activin A was restricted to LNCaP tumour cells and was not observed in other cell lines, such as PC3 cells. Specific assays for activin A detected measurable concentrations of activin A in PC3 cells, but not in LNCaP cells. Primary cultures of human prostatic epithelial cells produced measurable concentrations of activin A (Wang et al., 1999b) and growth of the cells was inhibited by exogenous activin A.
Regulation of activin ligand activity in prostate
A role for inhibin in the prostate has not been demonstrated. However, the inhibin α-subunit was localized to basal cells in the non-malignant epithelium together with activin βA-and βB-subunits (Mellor et al., 1998) , giving basal cells the capacity to synthesize both inhibins and activins. The basal cell layer of the epithelium consists of undifferentiated cells and includes the putative stem cells. Approximately 70% of proliferating cells in normal and hyperplastic acini are of the basal cell phenotype (Bonkhoff et al., 1994) . This cell layer does not usually contribute to glandular hyperplasia, except in rare instances of basal cell hyperplasia. Therefore, it is significant that inhibin α-subunit expression was identified in regions of basal cell hyperplasia in tissues from men with benign prostatic hypertrophy (Mellor et al., 1998) . It is possible that inhibin and activin have dual opposing roles in the regulation of epithelial cell proliferation, but this remains to be shown. All studies to date have used inhibin A, so it is important to determine the action of inhibin B in the prostate, as this may differ from inhibin A. As well as inhibin, follistatin was localized to basal cells, and the interplay between activin and follistatin may provide another level of regulation of the effects of activin. In the differentiated luminal secretory epithelium, activin βA, but not βB, inhibin α or follistatin, is expressed. This finding implies that activin regulates the proliferation of secretory epithelial cells unopposed by inhibin or follistatin in an autocrine manner. A paracrine effect of inhibin derived from neighbouring basal cells may regulate activin, but this would require the identification of inhibin receptors on the secretory cells. In non-malignant regions of prostate tissue from men with benign prostatic hypertrophy or prostate cancer, the basal epithelial cells have the capacity to synthesize all known activins and inhibins, and the secretory cells synthesize activin A and inhibin A. In the malignant epithelial tissue from men with high-grade prostate cancer, the capacity to produce inhibin is lost, but activin subunit expression is retained.
In tumour tissue from men with high grade prostate cancer, inhibin α expression is downregulated (Mellor et al., 1998) , and the addition of inhibin A to prostate tumour cell lines does not affect cell growth (McPherson et al., 1997) . Rather than inhibin, emerging evidence indicates that follistatin is a biologically important modulator of activin in the malignant and nonmalignant prostate. In LNCaP tumour cells and in primary cultures of human prostate epithelial cells, follistatin 288 isoform (FS288) neutralized the growth-inhibitory response to activin (McPherson et al., 1999; Wang et al., 1996) . Furthermore, the PC3 cells, which do not respond to exogenous activin A, produce concentrations of FS288 that are readily detected by the specific enzyme-linked immuno-sorbent assay (McPherson et al., 1999) . The endogenous production of FS288 may protect these cells from the growth inhibitory effects of activin A; indeed, it has been shown that addition of an antibody that blocks FS288 permits the PC3 cells to respond to exogenously added activin A (McPherson et al., 1999) . The co-localization of activin βA and follistatin in tumour cells is consistent with the notion that an autocrine response to activin A is regulated by follistatin in vivo (Thomas et al., 1998) .
In the human prostate, the relationship between the inhibitory action of activin A and the rapid growth characteristics of the tumour tissue is difficult to reconcile and presents an apparent anomaly. The explanation for this anomaly may lie in the fact that activins have multiple actions on many cells. During tumourigenesis, it is necessary to suppress the immune response by the host and to promote other processes such as angiogenesis. Activins and follistatin are involved in immune suppression and alter the effects of interleukin 1 and 6 in the immune cascade (Ohguchi et al., 1998; Yu et al., 1998; Russell et al., 1999) , and also regulate angiogenesis (Kozian et al., 1997) . Therefore, the interplay between activin and follistatin in prostate cells can, in theory, promote immune suppression and angiogenesis as well as regulate the autocrine growth inhibitory action of activin on tumour cells, so that overall tumour progression is maintained and enhanced (Fig. 2) .
Other sites of activin production
Although the major sites of inhibin and activin synthesis in the male reproductive tract are the testis and prostate, activin βA has been detected in human fetal epididymis (Roberts, 1997) . In the epididymis, activin was localized to smooth muscle cells and is consistent with the authors' observation (unpublished) that βA is localized to smooth muscle of seminal vesicles. The role of activins in smooth muscle function in the male reproductive tract remains to be determined. Activin A and follistatin proteins were measured by specific assay in human seminal fluid (Anderson et al., 1998) . The functional significance of high concentrations of follistatin in seminal plasma is unknown, but represents protein secreted from the apical aspect of the epithelium. It is difficult to relate the concentrations of follistatin in seminal fluid to the paracrine or autocrine actions of follistatin within the epithelium or stroma of prostate or seminal vesicles.
Conclusion
Inhibins and activins were isolated as gonadal proteins that could regulate pituitary FSH. Subsequently, these proteins have been shown to regulate a range of tissues and systems beyond their role in reproduction. In this article, the literature pertaining to the male reproductive tract has been reviewed and it is concluded that activins are important factors that act at a local level to maintain appropriate cell-cell interactions, particularly in the testis and prostate. The challenge for the future is to use better techniques and reagents to identify the difference between the roles of individual activin proteins, that is, activin A versus activin B versus activin AB. Analysis of model systems such as the knock-in mice developed by Matzuk and colleagues (Brown et al., 1999) will permit us to understand whether these proteins are functionally redundant and if compensatory mechanisms are essential for maintaining reproductive function. In addition, it appears that activin signalling through Smad proteins converges with the pathway for TGFβ ligand signalling, raising the question of whether there are discrete and distinct differences in the actions of activin versus TGFβ ligands. Studying the role of activins has been interesting and unpredictable and promises to provide more challenges and excitement for the future. 
